The Parker Institute for Cancer Immunotherapy
About The Parker Institute for Cancer Immunotherapy
Products & Services
Specialties
Funding History
Debug: View Raw Funding Data
| # | Type | Amount Fields | Date Fields | Investors |
|---|---|---|---|---|
| 1 |
RT: Philanthropic Investment T: - FT: Philanthropic Investment |
A: 125000000 MR: - FA: $125 million FAN: 125000000 |
D: 2024-07-18 FD: 2024-07-18 |
- |
Growth Metrics
Team & Leadership
Sean Parker
Founder and Chairman, Parker Institute for Cancer Immunotherapy
Jeffrey Bluestone
Chief Executive Officer and President, Sonoma BioTherapeutics
Tony Coles
Chairperson of Cerevel Therapeutics and Chairman and Chief Executive Officer of TRATE Enterprises
Eric Esrailian
Chief, Vatche and Tamar Manoukian Division of Digestive Diseases, David Geffen School of Medicine at UCLA
Margaret Georgiadis
Co-Founder and CEO of Montai Therapeutics
Scott Gottlieb
Partner at New Enterprise Associates; Former Commissioner of the U.S. Food and Drug Administration
Recent News
The Parker Institute for Cancer Immunotherapy Announces New Product Launch
2 days agoCompany unveils innovative solution to transform the industry, expanding market reach and capabilities...
Read more →Leadership Team Expands with Industry Veteran
1 week agoNew executive brings 20+ years of experience to accelerate growth and strategic initiatives...
Read more →Company Recognized as Industry Leader
2 weeks agoReceives prestigious award for innovation and customer satisfaction in competitive market...
Read more →Key Competitors
Competitor Alpha
Series B · $50M raised
Competitor Beta
Series C · $120M raised
Competitor Gamma
Series A · $25M raised
Competitor Delta
Seed · $10M raised
Company Details
- Website
- parkerici.org
- Industries
- Healthcare
- Company Size
- ~340 employees (est.)
Similar Companies
Discover AI-powered company recommendations based on industry, funding, and team profiles.
Upgrade to ProTechnology Stack
Discover the backend, frontend, and infrastructure technologies powering this company's products.
Upgrade to Pro